Evidence map›Paper›PMID 24937231›Full record

ArticleHuman gene therapy2014

Modeling promising nonmyeloablative conditioning regimens in nonhuman primates.

Devikha Chandrasekaran, Betty Nakamoto, Korashon L Watts, Hans-Peter Kiem, Thalia Papayannopoulou

Open access · greenAbstract read
In one paragraph

Article in Human gene therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Efficient manufacturing and engraftment ofMolecular therapy. Methods & clinical development · 2023
    Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Devikha Chandrasekaran1 Clinical Research Division, Fred Hutchinson Cancer Research Center , Seattle, WA 98109.
Betty Nakamoto
Korashon L Watts
Hans-Peter Kiem
Thalia Papayannopoulou
University of Washington · USFred Hutch Cancer Center · US

Funding

Washington National Primate Research CenterP51OD010425 · OD · UNIVERSITY OF WASHINGTON · PI Mari Ostendorf · 2012 to 2026
$201.8M
VECTOR CONSTRUCTIONS FOR GENE THERAPY OF SICKLE CELL DISEASEP01HL053750 · NHLBI · UNIVERSITY OF WASHINGTON · PI RUSSELL, DAVID W · 1994 to 2014
$30.4M
CORE--VECTOR PRODUCTIONP30DK056465 · NIDDK · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BERNSTEIN, IRWIN D · 1999 to 2014
$14.9M
Vector ProductionP01AI097100 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI BEARD, BRIAN C · 2012 to 2016
$11.9M
Cord Blood Expansion/Transplantation Nonhuman PrimateR01HL084345 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI KIEM, HANS-PETER · 2006 to 2009
$2.8M
NHLBI NIH HHS HL053750NHLBI NIH HHS HL084345NIAID NIH HHS P01 AI097100NIDDK NIH HHS DK056465NIDDK NIH HHS P30 DK056465NIH HHS P51 OD010425
6 · The paper itself

Abstract

Minimal conditioning or even no conditioning would be the preferred preparation for most gene therapy applications for nonmalignant diseases. However, reduced intensity conditioning (RIC) regimens in patients with nonhematologic malignancies have not led to long-term engraftment unless a selective advantage was present for the transplanted donor cells. Similar findings have also been observed in a number of large animal studies. Inadequate myelosuppression levels were thought to be responsible for the outcomes. To address this issue several innovative protocols in small animals have been presented with selective hematopoietic myelosuppression and less systemic toxicity. Such protocols promised to curb the transplant-related morbidity and mortality in myeloablative conditioning and provide effective long-term engraftment, especially in patients with gene-corrected autografts. In the present study we have tested some of these promising RIC regimens in nonhuman primates, a clinically relevant large animal model. Our data suggest that transient myelosuppression induced by anti-c-Kit antibody in conjunction with low-dose irradiation may lead to long-term engraftment, albeit at low levels. The animals with busulfan conditioning with or without anti-c-Kit that received gene-modified autologous transplants with green fluorescent protein expression had similar myelosuppression, but failed long-term engraftment and despite immunosuppressive treatment had all the hallmarks seen previously in similar models without immunosuppression. Our preliminary data expand current knowledge of RIC and emphasize the need to explore whether specific and directed myelosuppression alone is adequate in the absence of microenvironmental modulation, or whether innovative combinations are necessary for safe and effective engraftment.

Indexed as

Genetic TherapyHematopoietic Stem Cell TransplantationTransplantation ConditioningAnimalsAntigens, CD34Disease Models, AnimalHumansImmunosuppression TherapyImmunosuppressive AgentsLentivirusMacacaTransplantation, AutologousAntigens, CD34Immunosuppressive Agents

Identifiers

PMID24937231
PMCPMC4270134
OpenAlexW2317467567

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.